These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16862848)

  • 41. Cell culture and infection system for hepatitis C virus.
    Kato T; Date T; Murayama A; Morikawa K; Akazawa D; Wakita T
    Nat Protoc; 2006; 1(5):2334-9. PubMed ID: 17406476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection.
    Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Bartolomé J; Pardo M; Carreño V
    J Med Virol; 2007 Mar; 79(3):236-41. PubMed ID: 17245725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Redox modulation of the hepatitis C virus replication complex is calcium dependent.
    Choi J; Forman HJ; Ou JH; Lai MM; Seronello S; Nandipati A
    Free Radic Biol Med; 2006 Nov; 41(9):1488-98. PubMed ID: 17023276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C.
    Inokuchi M; Ito T; Uchikoshi M; Shimozuma Y; Morikawa K; Nozawa H; Shimazaki T; Hiroishi K; Miyakawa Y; Imawari M
    J Med Virol; 2009 Apr; 81(4):619-27. PubMed ID: 19235854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-human primate surrogate model of hepatitis C virus infection.
    Akari H; Iwasaki Y; Yoshida T; Iijima S
    Microbiol Immunol; 2009 Jan; 53(1):53-7. PubMed ID: 19161559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel HCV replication mouse model using human hepatocellular carcinoma xenografts.
    Guévin C; Lamarre A; Labonté P
    Antiviral Res; 2009 Oct; 84(1):14-22. PubMed ID: 19622372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Genes Immun; 2007 Apr; 8(3):181-92. PubMed ID: 17230195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How does hepatitis C virus enter cells?
    Diedrich G
    FEBS J; 2006 Sep; 273(17):3871-85. PubMed ID: 16934030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of HCV recurrence: do the pretransplantation rules apply?
    Burton JR; Rosen HR
    Liver Transpl; 2006 Jul; 12(7):1044-8. PubMed ID: 16799952
    [No Abstract]   [Full Text] [Related]  

  • 51. [The mechanism of hepatitis C virus replication].
    Satoh S; Kato N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():116-20. PubMed ID: 26845914
    [No Abstract]   [Full Text] [Related]  

  • 52. [HCV. Virologic aspects].
    González JE; Quarleri J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S19-21. PubMed ID: 20214288
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C.
    Mohler M; Seipp S; Tox U; Stremmel W; Theilmann L; Goeser T
    Dig Dis Sci; 1996 Jun; 41(6):1276-7. PubMed ID: 8654164
    [No Abstract]   [Full Text] [Related]  

  • 54. [The biology of the hepatitis C virus].
    Trepo C; Bailly F
    Ann Gastroenterol Hepatol (Paris); 1994; 30(3):129-31. PubMed ID: 8067681
    [No Abstract]   [Full Text] [Related]  

  • 55. Liver disease: Quest to find new mouse models for liver diseases.
    Smith K
    Nat Rev Gastroenterol Hepatol; 2013 Sep; 10(9):501. PubMed ID: 23938451
    [No Abstract]   [Full Text] [Related]  

  • 56. [The recent breakthroughs in the understanding of host factors contributing to hepatitis C virus].
    Wang X; Cen S
    Bing Du Xue Bao; 2011 Sep; 27(5):481-93. PubMed ID: 21998962
    [No Abstract]   [Full Text] [Related]  

  • 57. [Entry mechanisms of HCV].
    Tani H; Matsuura Y
    Nihon Rinsho; 2011 May; 69 Suppl 4():47-51. PubMed ID: 22096892
    [No Abstract]   [Full Text] [Related]  

  • 58. [Research progress on hepatitis C virus entry receptors].
    Cheng M; Yang W
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):877-80. PubMed ID: 22553848
    [No Abstract]   [Full Text] [Related]  

  • 59. Hepatitis C Virus-From Discovery to Cure: The 2016 Lasker-DeBakey Clinical Medical Research Award.
    Bartenschlager RF; Rice CM; Sofia MJ
    JAMA; 2016 Sep; 316(12):1254-5. PubMed ID: 27623041
    [No Abstract]   [Full Text] [Related]  

  • 60. HCV and lipoproteins: is oxLDL an Achilles' heel of the Trojan horse?
    Dreux M; Cosset FL
    Hepatology; 2006 May; 43(5):903-5. PubMed ID: 16628665
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.